Staphylococcus aureus (teicoplanin susceptible), Coagulase negative Staphylococci, Streptococcus pneumoniae, Streptococcus spp., Enterococcus spp. (Teicoplanin susceptible), C. jeikeium, Clostridium spp., L. monocytogenes, Actinomyces
Teicoplanin inhibits polymerization of cell wall components in susceptible bacteria
Cmax: 53.5mg/L (after 3mg/kg dose); Half-life: 170 hours; Volume of distribution: 0.9-1.6L/kg; Protein binding: 90%
Hepatic: Abnormal LFTs
Other: Drug fever
Serious infections: 400mg-800mgIV q12h x 1-3 days, then maintenance dose daily
Renal failure: CrCl > 60mL/min: Standard dosing
CrCl 40-60mL/min: half normal dose q24h
CrCl < 40mL/min: one-third maintenance dose given
Hepatic failure: No dosing changes recommended at this time.
Warning: Cross allergenicity may occur between patient with true allergy to vancomycin and patients receiving teicoplanin
Ciprofloxacin: Single case report of concomitant administration leading to seizure
Therapeutic: Culture and sensitivities, serum levels, signs and symptoms of infection, white blood cell count
Toxic: Rare reports of ototoxicity. Audiograms recommended for long term therapy.